welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Microlin Bio to Acquire Nucleic Acid Therapeutic Assets of Marina Biotech
Microlin Bio, Inc., a development stage biotechnology company focused on the development of microRNA based therapeutics for cancer, and Marina Biotech, Inc., a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced that the companies have executed a term sheet under which Microlin intends to acquire Marina’s nucleic acid therapeutics assets.
expertly curated content related to this topic
-
Monica M. Bertagnolli, MDDr. Bertagnolli is Professor at Harvard ...
-
Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Poly...The purpose of this study is to determin...
-
Lucio BertarioDr. Lucio Bertario is the Head of the Un...
-
Kresimira Milas, MDDr. Kresimira Milas is a Board Certified...
-
James HillMr James Hill is Clinical Professor of C...
-
Global Quantitative Assessment of the Colorectal Polyp Burden in Familial Adenomatous Polyposis by Using a Web-based...BACKGROUND: Accurate measures of the to...
-
Mitchell W. DillonSenior Certified Genetic Counselor at Mo...